Radiation added to hormone therapy increases survival for men with prostate cancer

	Tweet

For men with locally advanced prostate cancer the addition of radiation treatment to anti-androgen hormone therapy reduces the risk of dying of prostate cancer by 50 percent compared to those who have anti-androgen hormone treatment alone, according to a randomized study presented September 22, 2008, at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting in Boston.

“This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer when radiation is added to their treatment plan,” Anders Widmark, M.D., lead author of the study and a professor in radiation oncology at Umea University in Umea, Sweden, said. “I would encourage men with locally advanced prostate cancer to talk to their doctor to see if they would be a good candidate for radiation therapy in addition to hormone treatment.”

Locally advanced prostate cancer is cancer that has grown close to the border or outside the prostate gland and into neighboring tissue, but has not spread into the lymph nodes or to other organs. In this study, anti-androgen hormone therapy is used to treat prostate cancer by blocking the stimulating effect of testosterone on the prostate cancer cells, to shrink the prostate cancer and slow down the growth of prostate cancer. External beam radiation therapy (also called radiotherapy) involves a series of daily treatments to acurately deliver radiation to the prostate. 

The study involved 880 patients with locally advanced prostate cancer who were randomly assigned to receive three months of intense hormone therapy (temporary castration) called total elimination of androgens in the body (total androgen blockade) followed by continuous anti-androgen therapy, allowing the testosterone to come back or the same hormonal treatment combined with radiation therapy between February 1996 to December 2002.

Findings show that 18 percent of patients who underwent hormone therapy alone died of prostate cancer, compared to nine percent of those who had both hormone and radiation treatment. The quality of life at four years after treatment was similar between the two groups, with the exception of decreased social function in the patients who had the combined treatment.

###

The abstract, “A Randomized Trial Comparing Antiandrogens With Or Without Radiotherapy in the Treatment Of Locally Advanced Prostate Cancer: Survival and Qol Outcome,” will be presented at the plenary session at 2:00 p.m. on Monday, September 22, 2008. To speak to the lead author of the study, Anders Widmark, M.D., please call Beth Bukata or Nicole Napoli September 21-24, 2008, in the ASTRO Press Room at the Boston Convention and Exhibition Center at 617-954-3377 or 617-954-3378. You may also e-mail them at or .

Contact: Nicole Napoli

703-839-7336
American Society for Therapeutic Radiology and Oncology

RELATED STORIES:
Finnish researchers find a compound that prevents the growth of prostate cancer cells   No link between alcohol and prostate cancer risk   Variances in patterns of care for patients with prostate cancer failing primary therapy   Prostate cancer gene test provides new early detection   Antioxidants don’t prevent prostate cancer: study   Link Uncovered Between Benign Prostatic Hyperplasia, NSAIDs   Many prostate cancers caught by screening won’t kill   Hormonal Dietary Supplements Might Promote Prostate Cancer Progression   New research sheds light on gene destruction linked to aggressive prostate cancer   Fit Friday: Reducing prostate cancer death risk, diet’s role in asthma, workout clothes   Higher vitamin K intake tied to lower cancer risks   University of Oklahoma Scientists Discover Way to Stop Pancreatic Cancer in Early Stages   September is National Prostate Cancer Awareness Month   Delaying therapy OK for low-risk prostate cancer   Screening for Prostate Cancer May Not Reduce Men’s Risk of Death   Prostate cancer therapy linked to bone loss   Few well performed studies address management of lymph node positive prostate cancer   Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear   Gleevec strangles drug-resistant, metastatic prostate cancer   Predictive model of prostate cancer risk   Obesity raises risk of prostate cancer recurrence   Too many old men get prostate cancer tests: study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]